Skip to content

Study · In vitro (cells) · mouse · 1999

8 results

Synthesis of 153N-6 analogues and structure-function analysis at murine melanocortin-1 (MC1) receptors.

Sahm UG, Olivier GW, Pouton CW

Peptides1 Jan 1999Cited by 5 (Europe PMC)

PMID10447099 (opens in a new tab)DOI10.1016/s0196-9781(99)00047-9 (opens in a new tab)PepBankPUB-10447099
Publisher pagePubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In murine B16 melanoma cells, 153N-6 inhibited native alpha-MSH action at the MC1 receptor.

    In plain wordsIn cells, 153N-6 inhibited native alpha-MSH action at the MC1 receptor.

    Peptide
    Nonapeptide-1
    Outcome
    DecreaseInhibition of native alpha-MSH action
    Study

    mousen: not reported in source

    B16 melanoma cells expressing native MC1 receptor
    Comparator
    Native alpha-MSH
    Outcome group
    Receptor activity and mechanism · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    153N-6 was able to inhibit the action of native alpha-MSH and the potent synthetic agonist, [Nle4,D-Phe7]alpha-MSH, at the murine MC1-R.
    1 context sentence
    Summary · context
    Here we report the receptor-binding affinities and biologic activities of 153N-6 and 17 selected alpha-MSH analogues at the native MCI receptor expressed by murine B16 melanoma cells.
  2. 02LabIn vitro (cells)Activity measurement

    In murine B16 melanoma cells, 153N-6 inhibited [Nle4,D-Phe7]alpha-MSH action at the MC1 receptor.

    In plain wordsIn cells, 153N-6 inhibited the synthetic agonist [Nle4,D-Phe7]alpha-MSH at the MC1 receptor.

    Peptide
    Nonapeptide-1
    Outcome
    DecreaseInhibition of synthetic agonist action
    Study

    mousen: not reported in source

    B16 melanoma cells expressing native MC1 receptor
    Comparator
    [Nle4,D-Phe7]alpha-MSH
    Outcome group
    Receptor activity and mechanism · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    153N-6 was able to inhibit the action of native alpha-MSH and the potent synthetic agonist, [Nle4,D-Phe7]alpha-MSH, at the murine MC1-R.
    1 context sentence
    Summary · context
    Here we report the receptor-binding affinities and biologic activities of 153N-6 and 17 selected alpha-MSH analogues at the native MCI receptor expressed by murine B16 melanoma cells.
  3. 03LabIn vitro (cells)Activity measurement

    In murine B16 melanoma cells, the Ki of 153N-6 was 9.0 X 10(-6) M.

    In plain wordsIn cells, the Ki of 153N-6 was 9.0 X 10(-6) M.

    Peptide
    Nonapeptide-1
    Outcome
    Not applicableMC1 receptor inhibition constant
    Study

    mousen: not reported in source

    B16 melanoma cells expressing native MC1 receptor
    Outcome group
    Receptor activity and mechanism · Skin and wound
    Studied dose
    Dose not stated

    Measurements

    Ki
    9 10(-6) M
    153N-6 at murine MC1 receptor

    Source sentences

    Summary
    (Ki of 153N-6 = 9.0 X 10(-6) M).
    1 context sentence
    Summary · context
    Here we report the receptor-binding affinities and biologic activities of 153N-6 and 17 selected alpha-MSH analogues at the native MCI receptor expressed by murine B16 melanoma cells.
  4. 04LabIn vitro (cells)Activity measurement

    In murine B16 melanoma cells, the Ki of 153N-6 was 439 times higher than that of alpha-MSH.

    In plain wordsIn cells, the Ki of 153N-6 was 439 times higher than that of alpha-MSH.

    Peptide
    Nonapeptide-1
    Outcome
    IncreaseKi versus alpha-MSH
    Study

    mousen: not reported in source

    B16 melanoma cells expressing native MC1 receptor
    Comparator
    alpha-MSH
    Outcome group
    Receptor activity and mechanism · Skin and wound
    Studied dose
    Dose not stated

    Measurements

    Relative Ki
    439 fold
    153N-6 versus alpha-MSH

    Source sentences

    Summary
    However, the Ki of 153N-6 was 439 times higher than that of alpha-MSH and 4475 times higher than that of [Nle4,D-Phe7]alpha-MSH;
    1 context sentence
    Summary · context
    Here we report the receptor-binding affinities and biologic activities of 153N-6 and 17 selected alpha-MSH analogues at the native MCI receptor expressed by murine B16 melanoma cells.
  5. 05LabIn vitro (cells)Activity measurement

    In murine B16 melanoma cells, the Ki of 153N-6 was 4475 times higher than that of [Nle4,D-Phe7]alpha-MSH.

    In plain wordsIn cells, the Ki of 153N-6 was 4475 times higher than that of [Nle4,D-Phe7]alpha-MSH.

    Peptide
    Nonapeptide-1
    Outcome
    IncreaseKi versus synthetic agonist
    Study

    mousen: not reported in source

    B16 melanoma cells expressing native MC1 receptor
    Comparator
    [Nle4,D-Phe7]alpha-MSH
    Outcome group
    Receptor activity and mechanism · Skin and wound
    Studied dose
    Dose not stated

    Measurements

    Relative Ki
    4475 fold
    153N-6 versus [Nle4,D-Phe7]alpha-MSH

    Source sentences

    Summary
    However, the Ki of 153N-6 was 439 times higher than that of alpha-MSH and 4475 times higher than that of [Nle4,D-Phe7]alpha-MSH;
    1 context sentence
    Summary · context
    Here we report the receptor-binding affinities and biologic activities of 153N-6 and 17 selected alpha-MSH analogues at the native MCI receptor expressed by murine B16 melanoma cells.
  6. 06LabIn vitro (cells)Activity measurement

    In murine B16 melanoma cells, 153N-6 binding affinity did not significantly differ from alpha-MSH(5-13).

    In plain wordsIn cells, 153N-6 binding affinity did not significantly differ from alpha-MSH(5-13).

    Peptide
    Nonapeptide-1
    Outcome
    No significant changeBinding affinity versus alpha-MSH(5-13)
    Study

    mousen: not reported in source

    B16 melanoma cells expressing native MC1 receptor
    Comparator
    alpha-MSH(5-13)
    Outcome group
    Receptor activity and mechanism · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The binding affinity of 153N-6 was not significantly different from alpha-MSH(5-13), but it was 232 times lower than alpha-MSH(4-13).
    1 context sentence
    Summary · context
    Here we report the receptor-binding affinities and biologic activities of 153N-6 and 17 selected alpha-MSH analogues at the native MCI receptor expressed by murine B16 melanoma cells.
  7. 07LabIn vitro (cells)Activity measurement

    In murine B16 melanoma cells, 153N-6 binding affinity was 232 times lower than that of alpha-MSH(4-13).

    In plain wordsIn cells, 153N-6 binding affinity was 232 times lower than that of alpha-MSH(4-13).

    Peptide
    Nonapeptide-1
    Outcome
    DecreaseBinding affinity versus alpha-MSH(4-13)
    Study

    mousen: not reported in source

    B16 melanoma cells expressing native MC1 receptor
    Comparator
    alpha-MSH(4-13)
    Outcome group
    Receptor activity and mechanism · Skin and wound
    Studied dose
    Dose not stated

    Measurements

    Binding affinity reduction factor
    232 fold
    153N-6 versus alpha-MSH(4-13)

    Source sentences

    Summary
    The binding affinity of 153N-6 was not significantly different from alpha-MSH(5-13), but it was 232 times lower than alpha-MSH(4-13).
    1 context sentence
    Summary · context
    Here we report the receptor-binding affinities and biologic activities of 153N-6 and 17 selected alpha-MSH analogues at the native MCI receptor expressed by murine B16 melanoma cells.
  8. 08LabIn vitro (cells)Mechanism

    In murine B16 melanoma cells, Pro6 and Phe10 were the most influential substitutions determining 153N-6 antagonist activity.

    In plain wordsIn cells, Pro6 and Phe10 were the most influential substitutions determining 153N-6 antagonist activity.

    Peptide
    Nonapeptide-1
    Outcome
    Not applicableDeterminants of antagonist activity
    Study

    mousen: not reported in source

    B16 melanoma cells expressing native MC1 receptor
    Outcome group
    Receptor activity and mechanism · Skin and wound
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Pro6 and Phe10 (with respect to alpha-MSH) were found to be the most influential substitutions that determined the antagonist activity of 153N-6.
    1 context sentence
    Summary · context
    Here we report the receptor-binding affinities and biologic activities of 153N-6 and 17 selected alpha-MSH analogues at the native MCI receptor expressed by murine B16 melanoma cells.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    27 Oct 2026, 18:20 UTC

    Study results updated

  2. Version 2

    27 Oct 2026, 16:32 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    13 Oct 2026, 16:31 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.